The Department of Health plans to extend the current AIDS drug tender to ensure that pharmaceutical manufacturers are ready to compete on supplying the new "wonder drug" dolutegravir, a cheaper and safer alternative to one of the components currently used in the three-drug cocktail provided by state institutions to most HIV patients. The current tender, valued at R14bn when it was announced in January 2015, was originally slated to end next March. Bids for the new tender will be called for once a sufficient number of generic dolutegravir products are registered with the Medicines Control Council (MCC) to ensure vigorous competition, the department’s deputy director-general for regulation and compliance Anban Pillay told a joint sitting of Parliament’s portfolio committees on economic development and health on Wednesday. "It will be significant for patients and save us money," he said. The drug has already been introduced in Kenya, a first in Africa where more than 25-million have th...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.